Piracetam as a therapeutic agent for doxorubicin-induced cognitive deficits by enhancing cholinergic functions and reducing neuronal inflammation, apoptosis, and oxidative stress in rats

HIGHLIGHTS

• who: Vasudevan Mani and colleagues from the Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia have published the paper: Piracetam as a Therapeutic Agent for Doxorubicin-Induced Cognitive Deficits by Enhancing Cholinergic Functions and Reducing Neuronal Inflammation, Apoptosis, and Oxidative Stress in Rats, in the Journal: Pharmaceuticals 2022, 1563 of 23/Nov/2022
• what: The study investigated the effect of_(PIRA; 200 or 400 mg/kg) against doxorubicin (DOX)-induced cognitive deficits in rat model. The neurodegenerative effect of DOX can be observed in this study as the DOX-induced . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.